Lupus Erythematosus, Systemic
"Lupus Erythematosus, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Below are MeSH descriptors whose meaning is more general than "Lupus Erythematosus, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Lupus Erythematosus, Systemic".
This graph shows the total number of publications written about "Lupus Erythematosus, Systemic" by people in this website by year, and whether "Lupus Erythematosus, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Lupus Erythematosus, Systemic" by people in Profiles.
Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus. Ann Rheum Dis. 2022 Dec; 81(12):1712-1721.
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828.
Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature. Ann Rheum Dis. 2022 10; 81(10):1428-1437.
Discovery and Functional Characterization of Two Regulatory Variants Underlying Lupus Susceptibility at 2p13.1. Genes (Basel). 2022 06 05; 13(6).
Pre-Clinical Autoimmunity in Lupus Relatives: Self-Reported Questionnaires and Immune Dysregulation Distinguish Relatives Who Develop Incomplete or Classified Lupus From Clinically Unaffected Relatives and Unaffected, Unrelated Individuals. Front Immunol. 2022; 13:866181.
Relationship Between a Vitamin D Genetic Risk Score and Autoantibodies Among First-Degree Relatives of Probands With Rheumatoid Arthritis and Systemic Lupus Erythematosus. Front Immunol. 2022; 13:881332.
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022 07; 81(7):962-969.
Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2022 08; 81(8):1143-1150.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 07; 81(7):951-961.
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 2022 03 17; 386(11):1034-1045.